ENDV (Endonovo Therapeutics) Current Accrued Expense: $6.46 Mil (As of Jun. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Endonovo Therapeutics Current Accrued Expense?

Endonovo Therapeutics ENDV -99.00% Current Accrued Expense is $6.46 Mil as of Jun. 2025.

Endonovo Therapeutics's Current Accrued Expense for the quarter that ended in Jun. 2025 was $6.46 Mil.

Endonovo Therapeutics's quarterly Current Accrued Expense increased from Dec. 2024 ($5.84 Mil) to Mar. 2025 ($6.15 Mil) and increased from Mar. 2025 ($6.15 Mil) to Jun. 2025 ($6.46 Mil).

Endonovo Therapeutics's annual Current Accrued Expense increased from Dec. 2022 ($3.54 Mil) to Dec. 2023 ($4.76 Mil) and increased from Dec. 2023 ($4.76 Mil) to Dec. 2024 ($5.84 Mil).

Endonovo Therapeutics Current Accrued Expense Related Terms

Endonovo Therapeutics Current Accrued Expense Historical Data

* Premium members only.

The historical data trend for Endonovo Therapeutics's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Endonovo Therapeutics Current Accrued Expense Chart

Endonovo Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Current Accrued Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.90 2.53 3.54 4.76 5.84

Endonovo Therapeutics Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.37 5.68 5.84 6.15 6.46

Endonovo Therapeutics Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

What does a Current Accrued Expense of $6.46 Mil mean?
Endonovo Therapeutics (ENDV) has a Current Accrued Expense of $6.46 Mil as of Jun. 2025. Current Accrued Expense records the total amount of accrued expenses. View historical data on Endonovo Therapeutics and its competitors.
Is Endonovo Therapeutics' Current Accrued Expense too high?
Endonovo Therapeutics' current Current Accrued Expense is $6.46 Mil.
How does Endonovo Therapeutics' Current Accrued Expense compare to RGBP and SIGY?
Endonovo Therapeutics' Current Accrued Expense of $6.46 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Accrued Expense for a Biotechnology company?
A good Current Accrued Expense depends on the Biotechnology industry context. However, Current Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Accrued Expense mean?
A high Current Accrued Expense can signal that a stock is expensive relative to its fundamentals. Current Accrued Expense records the total amount of accrued expenses. View historical data on Endonovo Therapeutics and its competitors. Endonovo Therapeutics's current Current Accrued Expense is $6.46 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Endonovo Therapeutics stock overvalued right now?
Endonovo Therapeutics (ENDV) has a current Current Accrued Expense of $6.46 Mil. The current Current Accrued Expense is $6.46 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Accrued Expense calculated?
Current Accrued Expense is calculated from a company's financial statements. For Endonovo Therapeutics (ENDV), the current Current Accrued Expense is $6.46 Mil as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Endonovo Therapeutics Business Description

Address 6320 Canoga Avenue, 15th Floor, Woodland Hills, CA, USA, 91367
Endonovo Therapeutics Inc develops, manufactures and distributes revolutionary medical devices that utilize Pulsed Electro Magnetic Field (PEMF) therapy that are focused on the rapid recovery of wounds and reduction of pain, edema and inflammation on and in the human body.